Victor Levitsky

Chief Scientific Officer at Targovax

Dr Levitsky is a seasoned internationally recognized expert in immunology, oncology, T-cell immunotherapy and immuno-oncology with in-depth knowledge of preclinical, translational and early stage clinical drug development. He brings extensive experience in pre-clinical drug development of protein-based biologics and small molecules. Dr Levitsky is a medical doctor with a PhD in Virology and post-doctoral training in tumor biology at Karolinska Institute, Sweden. He spent the first 20 years of his career as an academic research scientist, including Associate Professor positions at the Karolinska Institute in Sweden and the Johns Hopkins University School of Medicine in the USA. Before joining Targovax Dr Levitsky served as Tumor Immunology Leader and Senior Principal Scientist with Roche in Zurich, and his most recent position has been VP, Head of Oncology Research at Molecular Partners, Zurich, Switzerland. Dr Levitsky is a Swedish and Russian citizen and resides in Switzerland.

Location

Schlieren, Switzerland

Links


Org chart


Teams


Offices

This person is not in any offices


Targovax

Targovax (OSE: TRVX) is a clinical-stage biotechnology company developing immune activators to target hard-to-treat solid tumors.


Industries

Headquarters

Oslo, Norway

Employees

11-50

Links